HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CBD Self-Regulation? UK Trade Association Launches Three-Tier Certification System

Executive Summary

HBW Insight speaks to the founder of the UK's Association for the Cannabinoid Industry, Steve Moore, about the organization's new three-tier certification system for CBD products marketed in the country, designed to mirror the EU Novel Foods approval process as well as recent local regulatory changes. 

You may also be interested in...



UK CBD Industry Welcomes FSA Clarification On Novel Food Evidence Requirement

“With so little publicly available information on the safety of CBD we anticipate that directly relevant studies will be needed,” explains the UK Food Standards Agency, in response to confusion within the country's CBD industry. 

Unauthorized CBD Sold In Europe Most Likely To Originate From UK

The UK was the most likely source of unauthorized CBD food products sold in the EU in the first half of 2020, an analysis by HBW Insight reveals. Ireland and Spain are leading the way in cracking down on such products and informing neighboring countries of the risks posed.

European Hemp Players Join Forces To Make Legal CBD Market A Reality

Europe's hemp industry is tired of operating in limbo and wants to secure a fully regulated CBD market as soon a possible. Industry players will pool resources and invest €3.5m to win novel food approval for a number of different CBD products.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

RS149940

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel